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A B S T R A C T
The modes of infection and transmission of
Pneumocystis jiroveci remain unclear. This study
explored the relationship between the incidence
of infection and climatic factors. In total, 536 cases
of P. jiroveci infection were identified in the period
1994–1998, with an inverse correlation between
the incidence of Pneumocystis pneumonia and the
minimum mean ambient temperature (Spearman
correlation coefficient: r ) 0.30; p 0.02; ARIMA
model: r ) 0.250, p 0.07). The highest number of
cases occurred in winter (ANOVA test, p < 0.05),
and there was a clear season-related incidence of
P. jiroveci infection.
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Pneumocystis jiroveci, known previously as Pneu-
mocystis carinii f. sp. hominis [1], is an atypical
fungus that causes pneumonia in immunocom-
promised individuals. Despite the high prevalence
of P. jiroveci pneumonia (PCP) in such patients,
little is known about the epidemiology and modes
of transmission of this infection [2]. Generally,
PCP is considered to result from acquisition
de novo rather than reactivation of latent infection,
but inter-human transmission has been reported
[3,4]. If the air-borne infection hypothesis is
correct, the epidemiological pattern of P. jiroveci
infection could be similar to that observed for
other infectious respiratory illnesses, which have a
higher incidence in the colder months. The aim of
this study was to explore potential relationships
between the incidence of P. jiroveci infection and
different climatic factors in order to investigate the
possible seasonality of the infection.
All cases of P. jiroveci infection diagnosed from
January 1994 until December 1998 at the Virgen
del Rocı´o University Hospital, Seville, Spain were
reviewed retrospectively. This tertiary referral
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hospital specialising in infectious diseases serves
an area of 720 000 inhabitants, and is the diag-
nostic centre providing clinical services for a large
cohort of immunosuppressed patients, including
patients suffering from AIDS or autoimmune
diseases, and > 100 new recipients of solid organ
allografts annually.
The presence of P. jiroveci was investigated
under sterile conditions in sputum samples,
bronchoalveolar lavage fluids and samples
obtained by trans-thoracic needle aspiration.
Clinical specimens were examined by immu-
nofluorescence with monoclonal antibodies
(Pneumo-cell IF test; Cellabs, Brookvale, Austra-
lia). The mean minimum monthly temperature
and relative humidity data were obtained from
the National Institute of Meteorology at Seville’s
weather station. Since highly active anti-retroviral
therapy (HAART) in patients with HIV infection
was implemented in Spain at the end of 1996, the
present study also compared two periods (1994–
1996 and 1997–1998) to determine the possible
influence of this therapy on the number of cases of
P. jiroveci infection.
Differences between group means were ana-
lysed with the two-tailed Student’s t-test. Rela-
tionships between continuous variables were
assessed by the Spearman correlation coefficient
and by a time series model (ARIMA model)
including two factors; namely, the averages of
monthly minimum temperatures and monthly
mean humidity levels. The ANOVA test was used to
assess possible differences in the number of cases
of P. jiroveci infection according to season.
During the study period, 536 cases of pulmon-
ary P. jiroveci infection were identified: 131 cases
in 1994, 112 in 1995, 122 in 1996, 76 in 1997, and
95 in 1998. The mean number of P. jiroveci
infections by month was significantly higher in
the pre-HAART years (1994–1996) than in the
HAART period (1997–1998) (10.1 ± 3.8, 95% CI
8.83–11.45 vs. 7.1 ± 3.7, 95% CI 5.49–8.76;
p < 0.05). No differences were observed between
these periods in terms of the minimum mean
temperatures (13.3 ± 3.8C, 95% CI 11.6–15.0 vs.
13.6 ± 4.8 C, 95% CI 11.5–15.72). Most (82.8%) of
the cases were HIV-positive patients. The
monthly distribution (Fig. 1) shows that the high-
est incidence was in February (71 cases), followed
by March (59 cases) and January (50 cases).
For the entire study period, there was an
inverse correlation between the number of cases
of P. jiroveci infection and the minimum mean
temperature (Spearman correlation coefficient:
r 0.30; p 0.02). No relationship was observed
between the number of cases and the relative
humidity (Spearman correlation coefficient:
r 0.18; p 0.16). The ARIMA model’s parameters
showed a negative relationship for both the
monthly minimal temperature (r ) 0.250, p 0.07)
and for relative humidity (r ) 0.003, p 0.95).
Hence, minimal temperature appeared to be a
factor influencing the trend, but not humidity.
The mean number of cases of P. jiroveci infection,
when compared across the four seasons, showed
a significant difference (p < 0.05, ANOVA test), with
a higher mean number in winter than in other
seasons, but no significant differences were found
between spring, summer and autumn in a post-
hoc analysis (Table 1).
Although PCP occurs in all parts of the world,
and serological studies suggest a relatively high
Number cases of P. jiroveci infection Minimum mean temperature
Number cases of P. jiroveci
infection
55 71 59 43 36 48 25 42 42 51 28 36
Minimum mean
temperature
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Fig. 1. Monthly distribution of cases
of Pneumocystis jiroveci infection
(1994–1998) and the minimum mean
temperature.
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incidence of asymptomatic P. jiroveci infection in
most countries, the prevalence of infection varies
considerably between different geographical
areas. Factors that may contribute to geographical
differences in the prevalence of PCP are the
virulence characteristics of different P. jiroveci
strains and variations in climate [2].
The role of climate on the incidence of PCP has
been examined previously in patients with AIDS,
and a significantly greater incidence of PCP in
HIV-infected homosexual men from the USA has
been observed in colder cities compared to those
with warm climates [5]. Similar results have been
reported for different European countries [6].
Seasonal variations among PCP cases have been
evaluated in several reports, but no clear pattern
has been evident [7,8]. A study in the UK
demonstrated a higher incidence of Pneumocystis
pneumonia in January, but the possible correla-
tion with temperature was not examined in
detail [9].
The present study demonstrated a higher inci-
dence of P. jiroveci infection in the colder months
in a broad population of patients, including AIDS
and other immunosuppressed HIV-negative
patients, as well as immunocompetent individu-
als. The minimum mean temperature was the
main meteorological factor influencing P. jiroveci
infection. The seasonality of P. jiroveci infection
could result directly from increased infection
during the colder months, or could be a conse-
quence of other upper respiratory tract diseases
predisposing to subsequent PCP. The results also
support the hypothesis of air-borne transmission
of P. jiroveci. A decrease in the number of cases of
P. jiroveci infection was observed following the
implementation of HAART, although the changes
in incidence were less marked than expected,
probably because the number of P. jiroveci infec-
tions in HIV-seronegative patients remained
stable.
Although a more extensive validation of the
results will be necessary on a worldwide basis,
the finding that differences in the frequency of P.
jiroveci infection are linked with environmental
factors should enable low- and high-risk geo-
graphical areas for this infection to be defined.
Such information will be especially useful when
decisions on prophylactic or therapeutic measures
are being made.
A C K N O W L E D G E M E N T S
We are indebted to J. R. Lacalle (Faculty of Medicine,
University of Seville) for his invaluable contributions to the
statistical analysis. The work was supported by the 5th
Framework Programme of the European Commission (con-
tract number QLK2-2000-01369).
R E F E R E N C E S
1. Stringer JR, Beard CB, Miller RF, Wakefield AE. A new
name (Pneumocystis jiroveci) for Pneumocystis from humans.
Emerg Infect Dis 2002; 8: 891–896.
2. Hughes WT. Current issues in the epidemiology, trans-
mission, and reactivation of Pneumocystis carinii. Semin Re-
spir Infect 1998; 13: 283–288.
3. Keerly SP, Stringer JR, Baughman RP, Linke MJ, Walzer PD,
Smulian AG. Genetic variation among Pneumocystis carinii
hominis isolates in recurrent pneumocystosis.
J Infect Dis 1995; 172: 595–598.
4. Chaves JP, David S, Wauters JP, Van Melle G, Francioli P.
Transmission of Pneumocystis carinii from AIDS patients to
other immunosuppressed patients: a cluster of Pneumocystis
carinii pneumonia in a renal transplant patient. AIDS 1991;
5: 927–932.
5. Hoover DR, Graham NMH, Bacellar H et al. Epidemiologic
patterns of upper respiratory illness and Pneumocystis carinii
pneumonia in homosexual men. Am Rev Respir Dis 1991;
144: 756–759.
6. Delmas MC, Schwoebel V, Heisterkamp SH, Downs AM,
Ancelle-Park RA, Brunet JB. Recent trends in Pneumocystis
carinii pneumonia as AIDS-defining disease in nine Euro-
pean countries. J AIDS 1995; 9: 74–80.
7. Miller RF, Grant AD, Foley NM. Seasonal variation in
presentation of Pneumocystis carinii pneumonia. Lancet 1992;
339: 747–748.
8. Vanhems P, Hirschel B, Morabia A. Seasonal incidence of
Pneumocystis carinii pneumonia. Lancet 1992; 339: 1182.
9. Lubis N, Baylis D, Short A et al. Prospective cohort study
showing changes in the monthly incidence of Pneumocystis
carinii pneumonia. Postgrad Med J 2003; 79: 164–166.
Table 1. Seasonal association of cases of Pneumocystis
jiroveci infections
(a) Distribution of yearly cases of P. jiroveci infection by
season
1994 1995 1996 1997 1998 Total
Spring 29 25 28 18 27 127
Summer 24 31 26 9 19 109
Autumn 34 20 21 23 17 115
Winter 44 36 47 26 32 185
ANOVA test (inter-group analysis) p 0.001
(b) Analysis post hoc (joint multivariate)
Station (I) Station (J)
Mean
differences (I-J) p value* 95% CI (limits)
Winter Spring 3.87 0.033 0.20 7.53
Summer 5.07 0.002 1.40 8.73
Autumn 4.67 0.006 1.00 8.33
*p < 0.05 was considered to be statistically significant. No significant differences
were found between the seasons. CI denotes Bonferroni confidence intervals.
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